608964.fig.004a
(a)
608964.fig.004b
(b)
608964.fig.004c
(c)
608964.fig.004d
(d)
Figure 4: LBH589 reduces osteosarcoma tumour growth and drives osteoblast differentiation in vivo. (a) U2OS xenograft flank tumours treated with vehicle control or 10 mg/kg LBH589 i.p. daily for 6 days. Bar = 5 mm. (b) Tumour volume. Mean ± SEM. (c) Percentage body weight. Mean ± SEM. (d) Quantitative real-time PCR of U2OS xenograft tumours following 6 consecutive days of treatment with vehicle control for expression of osteoblast differentiation markers. * .